Compare UFG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | ATOS |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 24.1M |
| IPO Year | 2024 | 2010 |
| Metric | UFG | ATOS |
|---|---|---|
| Price | $0.56 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 86.1K | 54.2K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.53 |
| 52 Week High | $9.91 | $7.56 |
| Indicator | UFG | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 51.67 |
| Support Level | $0.45 | $0.58 |
| Resistance Level | $0.64 | $2.60 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 39.37 | 43.58 |
Uni-Fuels Holdings Ltd is a service provider of marine fuel solutions. It operates on an integrated business model, serving customers through two operating models: sales of marine fuels solutions and brokerage (i.e., acting as an intermediary between marine fuels suppliers and customers for a commission). The various marine fuel products offered by the company include very low sulfur fuel oil, high sulfur fuel oil, marine gas oil, and bio marine fuel. Its customers are mainly shipping companies and other fuel suppliers operating in market sectors such as bulk, tanker, offshore, container, general cargo, tug and barge, car carrier, cruise, yacht, and dredging. Geographically, the company derives maximum revenue from Singapore, and the rest from Malaysia, Hong Kong, China, and other regions.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.